CrossRef Heterogeneity of hepatic macrophages in MASLD/MASH: Lipid-associated programs, molecular mechanisms, spatial niches, and therapeutic implications Kaipeng Hu, Siyuan Liu, Shuyan Sheng, Shaobo Zhang, Binghua Li, Beicheng Sun, Anliang Xia iLIVER .2026
Option 2: Were not seeing a modification in breast cancer risk, were seeing benefits from reduction of risk of other diseases
However, research studies suggest that those taking Semaglutide as directed by a professional can lose up to 15% of their body weight on the medication
Some insurers are expanding coverage for patients who meet medical criteria, while others are cutting back due to sustainability concerns